复方血栓通胶囊联合康柏西普治疗非增殖期糖尿病视网膜病变的疗效

Effects of Fufang Xueshuantong Capsule combined with Conbercept on non-proliferative diabetes retinopathy

目的探讨复方血栓通胶囊联合康柏西普治疗非增殖期糖尿病视网膜病变的临床疗效。方法选择2021年1月至2023年12月浙江省丽水市人民医院104例非增殖期糖尿病视网膜病变患者。按照随机数字表法分为对照组(玻璃体内注射康柏西普治疗)和治疗组(玻璃体内注射康柏西普联合口服复方血栓通胶囊治疗),每组各52例,2组患者均连续治疗3个月。比较2组患者治疗后的最佳矫正视力(BCVA)、微血管瘤数、出血量面积、渗出量、眼底检查结果、黄斑厚度及不良反应。结果治疗3个月时,2组患者的各项指标差异均无统计学意义(P>0.05)。治疗组患者的BCVA高于对照组,差异有统计学意义(P<0.05)。治疗组治疗后的微血管瘤数、出血量面积、渗出量均低于对照组,差异有统计学意义(P<0.05)。治疗组患者光学相干断层扫描仪检查结果优于对照组,差异有统计学意义(P<0.05)。2组患者治疗后的不良反应差异无统计学意义(P>0.05)。治疗组治疗后的临床疗效高于对照组,差异有统计学意义(P<0.05)。结论复方血栓通胶囊联合康柏西普治疗糖尿病视网膜病变疗效确切,可提高患者视力水平,安全性高。

Objective To explore the clinical efficacy of Fufang Xueshuantong Capsule combined with Conbercept in the treatment of non-proliferative diabetes retinopathy.Methods A total of 104 patients with non-proliferative diabetes retinopathy admitted to Lishui People′s Hospital from January 2021 to December 2023 were selected;And these patients were randomly divided into a control group(treated with intravitreal injection of Con-bercept)and a treatment group(treated with intravitreal injection of Conbercept combined with oral Fufang Xueshuantong capsules)according to the random number table method,with 52 cases in each group.Both groups of patients were treated continuously for 3 months.The BCVA,number of microangiomas,bleeding area,exuda-tion,fundus examination results,macular thickness,and adverse reactions were compared between two groups after treatment.Results At 3 months of treatment,there was no statistically significant difference in various indicators between the two groups of patients(P>0.05).The number of BCVA letters in the treatment group was significantly higher than that in the control group,and there was a statistically significant difference(P<0.05).The number of microangiomas,bleeding area,and exudation in the treatment group were significantly lower than those in the con-trol group after treatment,and there was a statistically significant difference(P<0.05).The OCT test results of pa-tients in the treatment group were significantly better than those of the control group,and there was a statistically significant difference(P<0.05).There was no statistically significant difference in adverse reactions between the two groups after treatment(P>0.05).The clinical efficacy of the treatment group after treatment was significantly higher than that of the control group,and there was a statistically significant difference(P<0.05).Conclusion Fufang Xueshuantong capsule combined with Conbercept is effective in the treatment of diabetes retinopathy,which can improve the visual acuity of patients with high safety.